Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Multiple sclerosis and the spinal cord.
[Differential diagnosis of late-stage neuroborreliosis with affection of the central nervous system.]
Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS.
Fast Whole-Brain Three-dimensional Macromolecular Proton Fraction Mapping in Multiple Sclerosis.
Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg).
Remyelination: The True Regeneration of the Central Nervous System.
Neuroendocrine Immunoregulation in Multiple Sclerosis.
Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis.
Melanocortins as Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives.
Therapeutic Armamentarium and Health System Coverage of Multiple Sclerosis in Latin America.
Kv1.3 Deletion Biases T Cells toward an Immunoregulatory Phenotype and Renders Mice Resistant to Autoimmune Encephalomyelitis.
Four different synthetic peptides of proteolipid protein induce a distinct antibody response in MP4-induced experimental autoimmune encephalomyelitis.
FDA approval of Isentress (raltegravir)
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Sphingolipids in ocular inflammation.
Anatomical Brain Networks on the Prediction of Abnormal Brain States.
Tysabri (natalizumab)
A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation.
Placebo power.
Couples coping with multiple sclerosis: a dyadic perspective on the roles of mindfulness and acceptance.
Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica.
A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica-immunoglobulin G binding to aquaporin-4.
Cannabinoids in the management of difficult to treat pain.
The causal cascade to multiple sclerosis: a model for MS pathogenesis.
HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis.
Pages
« first
‹ previous
…
226
227
228
229
230
231
232
233
234
…
next ›
last »